the present invention relates to a method of treatment of pc from the patient, a man in need of such treatment, including the introduction of the patient therapy combination of single drug form for oral application (e.g., a tablet or capsule) u0434 u0438 u043c u0435 u0442 u0438 u043b u0444 u0443 u043c u0430 u0440 u0430 u0442 u0430 and one agent selected from the u0442 u0435 u0440 u0438 u0444 u043b u0443 u043d u043e meade (or its prodrug u043b u0435 u0444 u043b u0443 u043d u043e u043c u0438 u0434 u0430), u0444 u0438 u043d u0433 u043e u043b u0438 u043c u043e u0434 u0430 and u043b u0430 u0445 u0438 u043d u0438 u043c u043e u0434 u0430.the combination of better individual agents and / or has fewer side effects and better portability than agents separately, and / or may be imposed with less frequency.in addition, the present invention is directed to a pharmaceutical composition suitable for oral treatment of multiple sclerosis, comprising u0434 u0438 u043c u0435 u0442 u0438 u043b u0444 u0443 u043c u0430 rata and one agent selected from the u0442 u0435 u0440 u0438 u0444 u043b u0443 u043d u043e u043c u0438 u0434 u0430, u0444 u0438 u043d u0433 u043e u043b u0438 u043c u043e u0434 u0430 and u043b u0430 u0445 u0438 u043d u0438 u043c u043e u0434 u0430 as active ingredients, and one or more u0444 u0430 u0440 u043c u0430 u0446 u0435 u0432 u0442 u0438 u0447 u0435 u0441 u043a u0438 acceptable u043d u0430 u043f u043e u043b u043d u0438 u0442 u0435 u043b u0435 u0439.Mevcut buluş, bu tür bir tedaviye ihtiyaç duyan bir insan hastada MS tedavisi için bir yöntem ile ilgilidir ve bahsedilen hastaya, tek bir oral dozaj formunda (örneğin, bir tablet veya kapsül) dimetilfumarat ve teriflunomid (veya bunun ön ilacı leflunomid) kombinasyon tedavisinin uygulanmasını içerir, bu tek başına tekli ajanlardan daha etkilidir ve/veya tek başına tekli ajanlara göre daha az yan etkiye ve daha iyi tolere edilebilirliğe sahiptir ve/veya düşük bir frekansta verilebilir. Ayrıca mevcut buluş, akt
